CLASP IID Trial and Registry
JACC: Cardiovascular Interventions · 2025
DOI: 10.1016/j.jcin.2025.07.014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Raj Makkar und 45 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: Raj.Makkar@cshs.org. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Mitral Valve, Heart Valve Prosthesis Implantation, Cardiac Catheterization. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Edwards Lifesciences Corp.
Abstract (Originalsprache)
BACKGROUND: One-year outcomes from the CLASP IID Trial (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial; NCT03706833) and Registry established the PASCAL transcatheter valve repair system as a safe and effective treatment for prohibitive-risk degenerative mitral regurgitation (DMR). Longer-term follow-up is ongoing. OBJECTIVES: This paper reports the CLASP IID Trial and Registry 2-year outcomes. METHODS: In the CLASP IID Trial, prohibitive-risk patients with 3+/4+ DMR, deemed suitable for both the PASCAL and MitraClip systems, were randomized 2:1 (PASCAL: n = 204; MitraClip: n = 96). Patients with complex anatomy deemed ineligible for randomization were enrolled in the CLASP IID Registry (N = 98) and treated with the PASCAL system. RESULTS: In the randomized cohort, significant and sustained MR reduction was achieved at 2 years. MR ≤2+ rate was 95.0% (96/101) in the PASCAL group vs 91.5% (54/59) in the MitraClip group (P = 0.500), and MR ≤1+ rate was 77.2% (78/101) vs 67.8% (40/59) (P = 0.198), respectively. Kaplan-Meier estimates for freedom from all-cause mortality, cardiovascular mortality, heart failure hospitalization, and nonelective mitral valve reinterventions were 80.8% vs 86.2% (P = 0.216), 88.6% vs 90.4% (P = 0.666), 86.4% vs 94.3% (P = 0.058), and 97.9% vs 97.9% (P = 0.962), respectively. In the registry cohort, 91.9% (34/37) achieved MR ≤2+ and 64.9% (24/37) achieved MR ≤1+. Kaplan-Meier estimates for freedom from all-cause mortality, cardiovascular mortality, heart failure hospitalization, and nonelective mitral valve reinterventions were 77.2%, 84.0%, 85.1%, and 99.0%, respectively. Significant improvements in functional status and quality of life were observed in both cohorts. CONCLUSIONS: Two-year outcomes from the CLASP IID Trial and Registry show favorable survival, and significant and sustained MR reduction with functional and quality-of-life improvements, confirming sustained safety and effectiveness of the PASCAL system in treating a broad population of DMR patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: Raj.Makkar@cshs.org.
- Oregon Health & Science University, Portland, Oregon, USA.
- Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Oregon Health & Science University, Portland, Oregon, USA. Electronic address: https://twitter.com/PDXHeartValveMD.
- University Medical Centre Mainz, Mainz, Germany. Electronic address: https://twitter.com/TobiasFRuf.
- Atlantic Health System Morristown Medical Center, Morristown, New Jersey, USA.
Förderung
- Edwards Lifesciences Corp
Zitieren
APA
Makkar, R., Zahr, F., Chakravarty, T., Chadderdon, S., Makar, M., Ruf, T. F., Kipperman, R. M., Rassi, A. N., Hausleiter, J., Smith, R. L., Szerlip, M., Goldman, S., Lim, D. S., Inglessis-Azuaje, I., Yadav, P., Lurz, P., Kister, T., Davidson, C. J., Mumtaz, M., …, & CLASP IID Trial and Registry Investigators (2025). CLASP IID Trial and Registry. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.07.014
Vancouver
Makkar R, Zahr F, Chakravarty T, Chadderdon S, Makar M, Ruf TF, et al. CLASP IID Trial and Registry. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.07.014
BibTeX
@article{Makkar2025,
author = {Makkar, Raj and Zahr, Firas and Chakravarty, Tarun and Chadderdon, Scott and Makar, Moody and Ruf, Tobias Friedrich and Kipperman, Robert M and Rassi, Andrew N and Hausleiter, Jörg and Smith, Robert L and Szerlip, Molly and Goldman, Scott and Lim, D Scott and Inglessis-Azuaje, Ignacio and Yadav, Pradeep and Lurz, Philipp and Kister, Tobias and Davidson, Charles J and Mumtaz, Mubashir and Gada, Hemal and Kar, Saibal and Kodali, Susheel K and Laham, Roger and Hiesinger, William and Fam, Neil P and Keßler, Mirjam and O'Neill, William W and Whisenant, Brian and Kliger, Chad and Rudolph, Volker and Hermiller, James and Dhoble, Abhijeet and Smalling, Richard and Latib, Azeem and Lazkani, Mohamad and Choo, Joseph and Garcia, Santiago and Rodés-Cabau, Josep and Schofer, Niklas and Baldus, Stephan and Kapadia, Samir and Koulogiannis, Konstantinos and Marcoff, Leo and Gillam, Linda D and von Bardeleben, Ralph Stephan and CLASP IID Trial and Registry Investigators, CLASP IID Trial and Registry Investigators},
title = {CLASP IID Trial and Registry},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
doi = {10.1016/j.jcin.2025.07.014}
}
EUVIMED